|
| |
| | CHEST: Interleukin-1[beta] gene polymorphisms associated with COPD |
 | | We thank Dr. Asada and colleagues for their comments on our article in CHEST (December 2004), (1) and we appreciate the opportunity to respond. | | | (2,3) Table 1 shows the characteristics of 85 COPD patients and 68 healthy subjects and the distribution of IL-1[beta] -511 and -31 genotypes in these two groups. | | | Polymorphisms of the interleukin-1[beta] gene are associated with increased risk of non-small cell lung cancer. |
|
http://www.findarticles.com/p/articles/mi_m0984/is_2_128/ai_n15335744
(1293 words)
|
|
| |
| | INABIS '98 - Illness, Cytokines, and Depression |
| | The aim of the present review is to present the current knowledge on the role of cytokines in mediating the depressive-like symptoms that accompany various medical conditions in humans and experimental models of these conditions in animals. | | | Most immune challenges produce their initial effects in the periphery, but information regarding their presence is almost immediately transmitted to the brain, in a sensory-like process. | | | Within the brain, this immune-related information activates several areas, and induces glia cells and neurons to release cytokines (such as interleukin (IL)-1, tumor necrosis factor-alpha (TNF-alpha), which serve as neurotransmitters and neuroregulators (Dantzer et al., 1996; Maier & Watkins, 1998). |
|
http://www.mcmaster.ca/inabis98/anisman/yirmiya0194/two.html
(3113 words)
|
|
| |
| | Kineret® - Interleukin-1 |
| | patients vs. less than 1% in placebo patients). | | | (anakinra) is indicated for the reduction in signs and symptoms and slowing the progression of structural damage in moderately to severely active rheumatoid arthritis, in patients 18 years of age or older who have failed 1 or more disease-modifying antirheumatic drugs (DMARDs). |
|
http://www.kineretrx.com/professional/about_il-1/interleukin-1.jsp
(337 words)
|
|
| |
| | Diabetes: Treatment with an interleukin-1 receptor antago... @ HighBeam Research |
| | Both patients had been given 15-deoxyspergaulin during the first 10 days posttransplantaion, and beneficial effects of this treatment were attributed to a blunting of the primary nonfunction. | | | The activiation of effector mechanisms, both specific and nonspecific, may depend on the production of cytokines [1]. | | | Furthermore, it has been shown that human IRAP can protect vitro [7,8]. |
|
http://www.highbeam.com/library/doc0.asp?DOCID=1G1:14674906&refid=holomed_1
(3452 words)
|
|
| |
| | Levels of T-lymphocyte subpopulations, interleukin-1 beta, and soluble interleukin-2 receptor in acute myocardial ... |
| | Group A (13 patients) experienced reinfarction; group B (26 patients) did not. | | | T-helper and-suppressor cells were measured by the indirect immunofluorescence method and sIL-2R and IL-1 serum levels by enzyme-linked immunosorbent assay (ELISA) methods on days 1, 4, and 7 after AMI. | | | High sIL-2R levels were found in groups A and B of the AMI patients as compared with the control group (p < or = 0.05).(ABSTRACT TRUNCATED AT 250 WORDS) |
|
http://www.aegis.com/aidsline/1994/aug/M9480646.html
(440 words)
|
|
| |
| | NEJM -- The Role of Interleukin-1 in Disease |
| | Potential therapeutic uses of interleukin 1 receptor antagonists in human diseases. | | | Imbalance of the interleukin 1 system in colonic mucosa---association with intestinal inflammation and interleukin 1 receptor agonist genotype 2. | | | Increased secretion of pro-inflammatory cytokines by circulating polymorphonuclear neutrophils and regulation by interleukin 10 during intestinal inflammation. |
|
http://content.nejm.org/cgi/content/short/328/2/106
(2225 words)
|
|
| |
| | Interleukin-1 Inhibition at Treatment for Rheumatoid Arthritis on Johns Hopkins Arthritis |
| | The risk of serious infections of anakinra in combination with a TNF inhibitor is unknown, but preliminary data in a small-uncontrolled study of 58 RA patients suggest an increase (7%) relative to anakinra alone. | | | A modest increase in the risk of serious infection was observed in RA patients treated with anakinra in combination with DMARDS other than TNF inhibitors, compared to placebo with DMARDs (2 % vs 1%). | | | However, neutralizing antibodies were rare, and the presence of antibodies did not appear to correlate with clinical response or adverse events. |
|
http://www.hopkins-arthritis.som.jhmi.edu/rheumatoid/il1.html
(3951 words)
|
|
| |
| | HON Allergy Glossary Interleukin1 (IL1) |
| | Corticosteroids, produced by the adrenals in response to signals from the brain (cortisone), inhibit the action of IL1 and are therefore used to reduce inflammation. | | | Inducing adhesion molecule expression on vascular endothelium is part of the inflammation syndrome - IL1 induces ICAM 1 expression, while TNFalpha induces ELAM 1 expression on endothelium. | | | These secretions are involved in inflammation, accounting in part for such inflammatory characteristics as vasodilation, cramps, fever and can produce a wasting syndrome called cachexia. |
|
http://www.hon.ch/Library/Theme/Allergy/Glossary/il1.html
(189 words)
|
|
| |
| | A multicentre, double blind, randomised, placebo controlled trial of anakinra (Kineret), a recombinant interleukin 1 ... |
| | A multicentre, double blind, randomised, placebo controlled trial of anakinra (Kineret), a recombinant interleukin 1 receptor antagonist, in patients with rheumatoid arthritis treated with background methotrexate | | | A multicentre, double blind, randomised, placebo controlled trial of anakinra (Kineret), a recombinant interleukin 1 receptor antagonist, in patients with rheumatoid arthritis treated with background methotrexate -- Cohen et al. | | | Updated consensus statement on biological agents, specifically tumour necrosis factor {alpha} (TNF{alpha}) blocking agents and interleukin-1 receptor antagonist (IL-1ra), for the treatment of rheumatic diseases, 2005 |
|
http://www.annrheumdis.com/cgi/content/abstract/63/9/1062
(529 words)
|
|
| |
| | INTERLEUKIN 1 BETA (IL-1 beta) antibodies from Research Diagnostics Inc |
| | 1 pg/ml of human IL1B is equivalent to 1 unit of activity in this assay. | | | We are not responsible for any patent infringements that might result with the use of or derivation of this products. | | | Application -Neutralization:approx 20ug/ml will neutralize 100% of 9 pg/ml recombinant human IL1B. |
|
http://www.researchd.com/cytokines/il1bab.htm
(556 words)
|
|
| |
| | Recombinant Human Interleukin-1 alpha - CYT-253 |
| | Less than 1% as determined by silver-stained SDS-PAGE gel analysis. | | | The ED50 as determined by the dose-dependant stimulation of murine D10S cells is less then 0.001 ng/ml, corresponding to a Specific Activity of 1 x 10 IU/mg. | | | [Content of tumor necrosis factor alpha and interleukin 1-alpha in patients with acute purulent pleural cavity] |
|
http://www.prospec.co.il/~prospec/cart/catalog/rHuIL1a.html
(521 words)
|
|
| |
| | Inhibitors of interleukin-1βconverting enzyme (US5843904) |
| | W. Griffin et al., "Brain Interleukin 1 and S-100 Immunoreactivity are Elevated in Down Syndrome and Alzheimer Disease", Proc. | | | M. Kostura et al., "Identification of a Monocyte Specific Pre-Interleukin 1β Convertase Activity", Proc. | | | G. Lonnemann et al., "Differences in the Synthesis and Kinetics of Release of Interleukin 1α, Interleukin 1β and Tumor Necrosis Factor from Human Mononuclear Cells", Eur. |
|
http://www.delphion.com/details?pn=US05843904__&language=en
(1449 words)
|
|
| |
| | Critical Role of Interleukin-1 in Rheumatoid Arthritis (IL-1) |
| | In particular, IL-1 is a potent stimulator of synoviocytes, chondrocytes and osteoblasts (Figure 1). | | | IL-1 has a pivotal role in the pathophysiology of RA, and acts on a range of cell types in the joint space to amplify and perpetuate the RA disease process. | | | Figure 1 IL-1 is a pivotal cytokine involved in the pathophysiology of RA |
|
http://www.kineret-eu.com/en/pro/rhe/rherol.jsp
(1015 words)
|
|
| |
| | Interleukin 1 |
| | This can have at least two effects: first, extracellular matrix degradation can facilitate monocyte migration, and second, MMPs are known to degrade IL-1ß, thus down-modulating the local inflammatory response initiated by IL-1. | | | Interleukin 1 (IL-1) is a general name for two distinct proteins, IL-1a and IL-1ß, that are considered the first of a small (but possibly growing) family of regulatory and inflammatory cytokines. | | | This complex then recruits IL-1 RAcP (bound to cytosolic serine/threonine kinases) to create a 200 kDa complex with a Kd of 250 pM, which results in IL-1/IL-1 R complex internalization and downstream activation. |
|
http://www.rndsystems.com/asp/g_sitebuilder.asp?bodyId=204
(789 words)
|
|
| |
| | Doxycycline--a role in ocular surface repair -- Smith and Cook 88 (5): 619 -- British Journal of Ophthalmology |
| | Table 1 Effect of doxycycline on MMP-2 activity | | | Figure 1 Effect of doxycycline on the zymographic activity profile of corneal MMP-2 when included at varying concentration in incubation buffer containing 2 mM Ca (A) or 10 mM Ca Additional experiments in which doxycycline (0–200 µM) was included in the culture medium of corneal epithelial cells | | | on 9% polyacrylamide gels after reduction (1% v/v mercaptoethanol) |
|
http://www.bjophthalmol.com/cgi/content/full/88/5/619
(3992 words)
|
|
| |
| | Mutant Cells That Do Not Respond to Interleukin-1 (IL-1) Reveal a Novel Role for IL-1 Receptor-Associated Kinase -- Li ... |
| | This article has been cited by other articles: | | | Burns, K., Janssens, S., Brissoni, B., Olivos, N., Beyaert, R., Tschopp, J. Inhibition of Interleukin 1 Receptor/Toll-like Receptor Signaling through the Alternatively Spliced, Short Form of MyD88 Is Due to Its Failure to Recruit IRAK-4. | | | Jiang, Z., Johnson, H. J., Nie, H., Qin, J., Bird, T. A., Li, X. Pellino 1 Is Required for Interleukin-1 (IL-1)-mediated Signaling through Its Interaction with the IL-1 Receptor-associated Kinase 4 (IRAK4)-IRAK-Tumor Necrosis Factor Receptor-associated Factor 6 (TRAF6) Complex. |
|
http://mcb.asm.org/cgi/content/abstract/19/7/4643
(1827 words)
|
|
|
